Skip to content
+1-516-222-6222
LCS@lachmanconsultants.com
Search
Location Selector

Current Location

  • - Global Website

  • - Ireland Website
  • Services
    • FDA-Related Services
    • Compliance
    • Regulatory Affairs
    • FDA 483 Response
    • Data Integrity
    • Mock FDA Inspections
    • Analytical Services
    • Biomonitoring Support
    • Strategic Planning
    • Due Diligence Audits
    • Quality Assurance and Controls
    • Scientific and Technical Assistance
    • Systems Evaluation
    • Facilities Design or Validation
    • System Process Validation or Qualification
    • Training
    • Remote Services From Lachman
  • Markets
    • Biologics
    • Advanced Therapies
    • Pharmaceuticals
    • Medical Devices
    • Related Industries
  • About
    • Lachman Leadership Team
    • Lachman Board of Directors
    • Careers
  • Blog & News
    • Blog
    • News
  • Contact
  • Resources
    • Lachman Learning
  • Location Selector
    • – Global Website
    • – Ireland Website

Reports

Lachman Consultant Services, Inc. / Blog / Reports
21
Mar

BLA One Time Report Deadline Coming Soon

By Bob Pollock    Mar 21, 2023    Biologics BLA FDA Regulatory Affairs Reports

An email from the FDA explained that on March 17, 2023 the FDA added information to the Purple Book Database of Licensed Biological Products (here) to include information on new reporting requirements established by the Section 3201 of the Consolidated Appropriations Act of 2023.  According to the Purple Book Q&A #8: “Section 506I(c) of the […]

Read More

Subscribe to our blog

Recent Articles

  • Patent Listings by NDA Sponsors: The Who, What, Why, Where, and How Q&A Document
  • Last Chance to Influence SUPAC Revisions!
  • Sunscreen Ingredient Receives GRASE Status

Contact Us:



Since 1978, Lachman Consultants’ multidisciplinary team of highly experienced FDA and industry experts has offered compliance, regulatory affairs, and technical services to clients around the world.
+1-516-222-6222
LCS@lachmanconsultants.com

 

Subscribe to our blog

Quick Links

  • Home
  • About
  • Services
  • Markets
  • Careers
  • Blog
  • Contact

Recent Posts

  • Patent Listings by NDA Sponsors: The Who, What, Why, Where, and How Q&A DocumentPatent Listings by NDA Sponsors: The Who, What, Wh…
    June 12, 2026
  • Last Chance to Influence SUPAC Revisions!Last Chance to Influence SUPAC Revisions!
    June 10, 2026
  • Sunscreen Ingredient Receives GRASE Status
    June 9, 2026
2026 © Lachman Consultant Services, Inc.Terms and ConditionsPrivacy PolicyFCOI Policy
  • Services
    ▼
    • FDA-Related Services
    • Compliance
    • Regulatory Affairs
    • FDA 483 Response
    • Data Integrity
    • Mock FDA Inspections
    • Analytical Services
    • Biomonitoring Support
    • Strategic Planning
    • Due Diligence Audits
    • Quality Assurance and Controls
    • Scientific and Technical Assistance
    • Systems Evaluation
    • Facilities Design or Validation
    • System Process Validation or Qualification
    • Training
    • Remote Services From Lachman
  • Markets
    ▼
    • Biologics
    • Advanced Therapies
    • Pharmaceuticals
    • Medical Devices
    • Related Industries
  • About
    ▼
    • Lachman Leadership Team
    • Lachman Board of Directors
    • Careers
  • Blog & News
    ▼
    • Blog
    • News
  • Contact
  • Resources
    ▼
    • Lachman Learning
  • Location Selector
    ▼
    • – Global Website
    • – Ireland Website
Manage Consent

We use cookies and similar technologies to improve site performance, personalize content, analyze traffic, and for marketing purposes. You can accept all cookies, reject non-essential cookies, or manage your preferences. You may change or withdraw your consent at any time in our Cookie Settings.

Functional Always active
The technical storage or access is strictly necessary for the legitimate purpose of enabling the use of a specific service explicitly requested by the subscriber or user, or for the sole purpose of carrying out the transmission of a communication over an electronic communications network.
Preferences
The technical storage or access is necessary for the legitimate purpose of storing preferences that are not requested by the subscriber or user.
Statistics
The technical storage or access that is used exclusively for statistical purposes. The technical storage or access that is used exclusively for anonymous statistical purposes. Without a subpoena, voluntary compliance on the part of your Internet Service Provider, or additional records from a third party, information stored or retrieved for this purpose alone cannot usually be used to identify you.
Marketing
The technical storage or access is required to create user profiles to send advertising, or to track the user on a website or across several websites for similar marketing purposes.
  • Manage options
  • Manage services
  • Manage {vendor_count} vendors
  • Read more about these purposes
View preferences
  • {title}
  • {title}
  • {title}